← Leaderboards
Khalid A Shah
Massachusetts General Hospital
$15,720,802
Attributed
$15,720,802
Total exposure
12
Grants
12
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.6M · FY2008–25$2M$1.5M$1M$500K$0
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$15,720,802 · 12
By mechanism
R01$14,816,439 · 10
R21$904,363 · 2
Top collaborators
No co-investigators on record.
Most similar at Massachusetts General Hospital
Same institution · by research overlap
- Bakhos A. Tannous$11,831,527
- Samuel D Rabkin$6,893,969
- Robert L Martuza$21,256,149
- Melissa J Suter$7,981,792
- Christian Elias Badr$3,737,491
Others in their field
Top investigators on “Treatment Efficacy”
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$239,767,754
- Judith S. Currier · University Of California Los Angeles$224,898,605
- Joseph J. Eron · Univ Of North Carolina Chapel Hill$222,287,773
- Sharon A Nachman · Johns Hopkins University$213,337,729
- Kathryn Hirst · Caritas St. Elizabeth'S Medical Center$200,360,009
- Lawrence Corey · Fred Hutchinson Cancer Center$163,868,320
Research focus
Treatment EfficacyTumorDesignCollaborationsBrain NeoplasmsEngineeringNeoplastic CellMouse ModelBostonIn VivoCellsStem CellsLigandsBaseSiteGlioblastomaTumor GrowthMediatingMesenchymal Stem CellsPositron-Emission TomographyPublishingPrimary NeoplasmHuman EngineeringExcision
Grant awards (44)
Encapsulated Cell Based Oncolytic Virus Therapy for Brain Tumors$420,251
R01 · FY2025 · NS · contact PI
Cell surface receptor targeted therapies for brain tumors$417,858
R01 · FY2025 · CA · contact PI
Targeting metastatic tumors with engineered cellular therapies$400,053
R01 · FY2025 · CA · contact PI
Gene Edited and Engineered Tumor Cell Therapeutics for Cancer$373,424
R01 · FY2025 · NS · contact PI
Gene Edited and Engineered Tumor Cell Therapeutics for Cancer$402,467
R01 · FY2024 · NS · contact PI
Targeting metastatic tumors with engineered cellular therapies$385,097
R01 · FY2024 · CA · contact PI
Gene Edited and Engineered Tumor Cell Therapeutics for Cancer$442,270
R01 · FY2023 · NS · contact PI
Targeting metastatic tumors with engineered cellular therapies$405,478
R01 · FY2023 · CA · contact PI
Engineered and Encapsulated Stem Cells for Resected Brain Tumors$363,913
R01 · FY2023 · NS · contact PI
Gene Edited and Engineered Tumor Cell Therapeutics for Cancer$451,126
R01 · FY2022 · NS · contact PI
Engineered and Encapsulated Stem Cells for Resected Brain Tumors$363,913
R01 · FY2022 · NS · contact PI
Gene Edited and Engineered Tumor Cell Therapeutics for Cancer$466,689
R01 · FY2021 · NS · contact PI
Engineered and Encapsulated Stem Cells for Resected Brain Tumors$386,033
R01 · FY2021 · NS · contact PI
Fate and efficacy of targeted therapies for metastatic tumors$387,917
R01 · FY2020 · CA · contact PI
Engineered and Encapsulated Stem Cells for Resected Brain Tumors$386,033
R01 · FY2020 · NS · contact PI
In vivo imaging of the stem cell loaded oncolytic viruses for cancer therapy$347,224
R01 · FY2020 · CA · contact PI
Engineered and Encapsulated Stem Cells for Resected Brain Tumors$386,033
R01 · FY2019 · NS · contact PI
Fate and efficacy of targeted therapies for metastatic tumors$376,363
R01 · FY2019 · CA · contact PI
In vivo imaging of the stem cell loaded oncolytic viruses for cancer therapy$374,748
R01 · FY2019 · CA · contact PI
Fate and efficacy of targeted therapies for metastatic tumors$388,180
R01 · FY2018 · CA · contact PI
In vivo imaging of the stem cell loaded oncolytic viruses for cancer therapy$386,339
R01 · FY2018 · CA · contact PI
In vivo imaging of the stem cell loaded oncolytic viruses for cancer therapy$406,031
R01 · FY2017 · CA · contact PI
Fate and efficacy of targeted therapies for metastatic tumors$388,677
R01 · FY2017 · CA · contact PI
In vivo imaging of encapsulated stem cells in mouse models of tumor resection$334,659
R01 · FY2017 · CA · contact PI
In vivo imaging of Stem cell loaded oncolytic viruses for cancer therapy$374,428
R01 · FY2016 · CA · contact PI
In vivo imaging of encapsulated stem cells in mouse models of tumor resection$358,622
R01 · FY2016 · CA · contact PI
Fate and efficacy of targeted therapies for metastatic tumors$204,104
R01 · FY2016 · CA · contact PI
Fate and efficacy of targeted therapies for metastatic tumors$171,727
R01 · FY2016 · CA · contact PI
In vivo imaging of encapsulated stem cells in mouse models of tumor resection$358,843
R01 · FY2015 · CA · contact PI
Stem cell mediated targeting of tumor cells and associated vasculature in gliomas$374,742
R01 · FY2014 · NS · contact PI
In vivo imaging of encapsulated stem cells in mouse models of tumor resection$348,272
R01 · FY2014 · CA · contact PI
Developing diagnostic and therapeutic stem cells for cancer therapy$343,556
R01 · FY2014 · CA · contact PI
Stem cell mediated targeting of tumor cells and associated vasculature in gliomas$365,329
R01 · FY2013 · NS · contact PI
In vivo imaging of encapsulated stem cells in mouse models of tumor resection$334,659
R01 · FY2013 · CA · contact PI
Developing diagnostic and therapeutic stem cells for cancer therapy$332,994
R01 · FY2013 · CA · contact PI
Overcoming therapeutic resistance of gliomas$251,865
R21 · FY2013 · NS · contact PI
Stem cell mediated targeting of tumor cells and associated vasculature in gliomas$379,276
R01 · FY2012 · NS · contact PI
Developing diagnostic and therapeutic stem cells for cancer therapy$354,298
R01 · FY2012 · CA · contact PI
Overcoming therapeutic resistance of gliomas$218,021
R21 · FY2012 · NS · contact PI
Stem cell mediated targeting of tumor cells and associated vasculature in gliomas$374,244
R01 · FY2011 · NS · contact PI
Developing diagnostic and therapeutic stem cells for cancer therapy$354,365
R01 · FY2011 · CA · contact PI
Developing diagnostic and therapeutic stem cells for cancer therapy$346,204
R01 · FY2010 · CA · contact PI
In vivo imaging and therapeutic efficacy of NSC-secreted nanobodies$198,060
R21 · FY2009 · CA · contact PI
In vivo imaging and therapeutic efficacy of NSC-secreted nanobodies$236,417
R21 · FY2008 · CA · contact PI